RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope

To date, gene therapy with transiently derived lentivectors has been very successful to cure rare infant genetic diseases. However, transient manufacturing is unfeasible to treat adult malignancies because large vector lots are required. By contrast, stable manufacturing is the best option for high-...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Ther Methods Clin Dev
Главные авторы: Marin, Virna, Stornaiuolo, Anna, Piovan, Claudia, Corna, Stefano, Bossi, Sergio, Pema, Monika, Giuliani, Erica, Scavullo, Cinzia, Zucchelli, Eleonora, Bordignon, Claudio, Rizzardi, Gian Paolo, Bovolenta, Chiara
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2016
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4863723/
https://ncbi.nlm.nih.gov/pubmed/27222840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mtm.2016.33
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы